LMBP2-specific TCR-T cell therapy (TCRCure Biopharma)

N/A

Report date: 2024/11/07 13:31:39

Base Information

Drug NameLMBP2-specific TCR-T cell therapy (TCRCure Biopharma)
Drug Alias NameLMP2-Specific IL12-secreting TCR-T Cell therapy (TCRCure Biopharma)LMBP2-specific TCR-T cell with IL12 auto-secreting element (TCRCure Biopharma)EBV TCR-T (TCRCure Biopharma)LMBP2-specific TCR-T cells (TCRCure Biopharma)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionLatent membrane protein 2 modulatorsInterleukin-2 modulatorsT lymphocyte replacements
TargetsLatent membrane protein 2Interleukin-2
Therapy Area/IndicationsNasopharyngeal Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesTcrcure Biopharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTcrcure Biopharma Ltd
Inactive CompaniesN/A
Active IndicationsNasopharyngeal Carcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A